· Published by Health Canada · Official notice
This is duplicated text of a letter from Baxter Corporation. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
June 10, 2013
Subject: Missing French label information, including Product Information Leaflet, regarding hypersensitivity to egg-, soya- or peanut protein for Intralipid 10%, 20% and 30% Fat Emulsion for Intravenous Infusion (DINs: 02065681, 02065673, 02216175).
Dear Health Care Professional,
Fresinius Kabi AB, in collaboration with Health Canada, would like to inform you about important missing information on the French label regarding "Contraindications" and "Warnings" in the Product Information Leaflet and "Cautions" on the pouch label for Intralipid 10%, 20% and 30% Fat Emulsion for intravenous infusion indicated for nutritional supplementation.
Hypersensitivity to egg-, soya- or peanut protein or to any of the active substances or excipients is contraindicated for the use of Intralipid. Since Intralipid contains soybean oil and egg phospholipids, there is a risk of allergic reaction in patients with egg-, soya- or peanut protein allergies (the latter due to potential cross reactions between peanuts and soybeans). Allergic reactions such as anaphylaxis can be serious and require immediate medical attention.
Specifically, there is a printing discrepancy between the English and French copy in the Product Information Leaflet that accompanies Intralipid and the Intralipid pouch label. The sentences that are missing in the French copy of the Product Information Leaflet are as follows:
Contraindications
Hypersensitivity to egg-, soya- or peanut protein or to any of the active substances or excipients is also contra-indicated.
French Text for Above: / Version française de l'anglais ci-dessus :
Contre-indications
Il est également contre-indiqué dans les cas d'hypersensibilité aux protéines d'œuf, de soya ou d'arachides, à l'une des substances actives de telles préparations ou à l'un des excipients de celles-ci.
Warnings:
Use in pregnancy
This medicinal product contains soya-bean oil and egg phospholipids which may rarely cause allergic reactions. Cross allergic reactions have been observed between soybean and peanut.
French Text for Above: / Version française de l'anglais ci-dessus :
Mise en garde:
Utilisation Durant la grossesse
Ce produit contient des phospholipides d'huile de soya et d'œuf, lesquels peuvent parfois provoquer des réactions allergiques. Des cas de réactions allergiques croisées entre le soya et les arachides ont été observés.
On the pouch label, the following information is missing:
Caution:
Contains soya-bean oil and egg phospholipid which may rarely cause allergic reactions. Cross allergic reactions have been observed between soybean and peanut.
French Text for Above: / Version française de l'anglais ci-dessus :
Précaution :
Contient des phospholipides d'huile de soya et d'œuf qui peuvent parfois provoquer des réactions allergiques. Des cas de réactions allergiques croisées entre le soya et les arachides ont été observés.
The English copy is complete. This discrepancy impacts the French labelling only.
The French product information leaflet is being revised and will be used in new production batches starting in June 2013. The pouch label will be revised by July 2013.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious allergic reaction or other serious or unexpected adverse reactions in patients receiving Intralipid should be reported to Baxter Corporation or Health Canada.
Baxter Corporation
7125 Mississauga Rd.
Mississauga, Ontario
L5N 0C2 Canada
Call 1-888-719-9955 between 7:00 a.m. and 7:00 p.m. Eastern Time, Monday through Friday or email: hospitalcare@baxter.com
To correct your mailing address or fax number, contact Baxter Corporation.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Product and Food Branch Inspectorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 613-946-5636
Sincerely,
original signed by
Alexander Stoll
Qualified Person
Fresenius Kabi, Plant Uppsala